Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

OpenAI Halts Stargate UK Data Centre Project Over Energy Costs and Copyright Row

Published

on

OpenAI has agreed a multibillion-dollar partnership with Advanced Micro Devices (AMD) to secure massive computing power for its next generation of artificial intelligence models — a direct challenge to Nvidia’s dominant position in the global AI chip market.

Sir Keir Starmer’s pledge to forge Britain into an artificial intelligence “superpower” has suffered its most embarrassing setback to date, after OpenAI quietly shelved its flagship Stargate UK data centre project, pointing the finger squarely at ruinous industrial energy prices and a muddled copyright regime.

The ChatGPT developer confirmed on Thursday that it was pausing the scheme, which had been unveiled with considerable fanfare last September during President Trump’s state visit. Stargate UK was meant to be the crown jewel in a £31 billion package of American technology commitments that also included £22 billion from Microsoft and £5 billion from Google. OpenAI, tellingly, never put a figure on its own pledge.

Built in partnership with chip giant Nvidia and London-based Nscale, the project was sold to ministers as a “major step” towards building sovereign British compute capacity, initially deploying some 8,000 graphics processing units in the first quarter of this year and scaling to roughly 31,000 chips thereafter. Sam Altman (pictured), OpenAI’s chief executive, had talked up its potential to turbocharge scientific research, lift productivity and juice economic growth, the very metrics the Labour government has staked its credibility on.

For the hundreds of thousands of small and mid-sized British firms eyeing AI as a route to efficiency and competitiveness, the climbdown is more than symbolic. Without domestic compute power at scale, SMEs risk being pushed further down the queue behind American and European rivals who can plug into cheaper, closer infrastructure.

Sam Richards, chief executive of the pro-infrastructure campaign group Britain Remade, did not mince his words. He described the pause as “a stark warning” that Britain was becoming prohibitively expensive to build in, arguing that no country saddled with some of the developed world’s steepest industrial electricity tariffs could credibly call itself an AI superpower. Investors, he warned, would simply take their chequebooks elsewhere.

Advertisement

An OpenAI spokesman insisted the company remained committed in principle, saying it would press ahead with Stargate UK once “the right conditions” on regulation and energy costs allowed for genuine long-term infrastructure investment. London, the spokesman noted, remained the firm’s largest international research hub, and OpenAI was continuing to expand its local headcount and roll out frontier AI tools within public services.

Behind the diplomatic language, however, lies a more pointed grievance. OpenAI made clear that the government’s U-turn on copyright reform was a significant factor in its decision. The company had been lobbying aggressively for a regime that would have permitted AI developers to hoover up copyrighted material to train their models unless rights holders explicitly opted out. After a fierce backlash from authors, musicians, publishers and much of the wider creative industries, ministers scrapped the proposal and now insist they have “no preferred option” on the way forward.

While the original Stargate announcement pitched the British chip cluster at “specialist use cases” in the public sector, regulated industries such as financial services, academic research and national security, OpenAI pointedly avoided any reference to training models on UK soil. The firm has now conceded it wanted the “freedom and the options” to deploy that local capacity as it saw fit — a euphemism, critics will say, for the very training activity at the heart of the copyright row.

The economics of the decision are, however, harder to spin away. Hyperscale data centres are voracious consumers of electricity, and the United Kingdom continues to lumber large industrial users with some of the highest power prices in the OECD. For a sector in which marginal costs dictate where the next gigawatt of capacity lands, Britain’s energy bill is an increasingly difficult sell in Silicon Valley boardrooms.

Advertisement

A Whitehall spokesman said the government was continuing to work with OpenAI and other leading AI firms “to strengthen UK compute capacity”, though officials privately acknowledge the optics are bruising.

The retreat also dovetails with a broader tightening of focus inside OpenAI itself. Valued at an eye-watering $852 billion at its most recent fundraising, the company is widely expected to press the button on a blockbuster stock-market flotation later this year, and has been busily jettisoning what insiders have dubbed “side quests”. In recent weeks it has pulled the plug on its Sora video-generation app, binned plans for an adult-oriented chatbot and quietly wound down an experiment in e-commerce.

Nscale declined to comment. Nvidia had not responded to a request for comment at the time of writing.

For British business, the message is uncomfortably clear: without urgent action on energy costs and regulatory clarity, the much-vaunted AI gold rush may end up passing these shores by.

Advertisement

Jamie Young

Jamie Young

Jamie is Senior Reporter at Business Matters, bringing over a decade of experience in UK SME business reporting.
Jamie holds a degree in Business Administration and regularly participates in industry conferences and workshops.

When not reporting on the latest business developments, Jamie is passionate about mentoring up-and-coming journalists and entrepreneurs to inspire the next generation of business leaders.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Thailand’s Virtual Bank Shortlist Reaches Pivotal Phase

Published

on

Thailand's Virtual Bank Shortlist Reaches Pivotal Phase

Thailand’s initiative to introduce virtual banks has entered a critical stage, with the Bank of Thailand (BOT) enforcing strict regulatory compliance for the three remaining applicants.

Candidates, which include major consortia involving entities like CP Group, Krung Thai Bank, and SCBX, are required to finalize their organizational and business structures to meet central bank standards.

Failure to adhere to these criteria or provide sufficient justification for deviations could result in the revocation of a licence, potentially leading to a market with fewer than three operators as there are no provisions to replace disqualified applicants.

Key Points

  • Finalists: The three applicants currently under review are ACM Holding (CP Group), a consortium led by Krung Thai Bank (with AIS and OR), and SCBX (partnering with KakaoBank and WeBank).
  • Compliance Requirements: Applicants must ensure that financial businesses are separated from non-financial entities to mitigate risks and prevent conflicts of interest, such as unauthorized lending or preferential pricing for affiliates.
  • Adjustments: To meet criteria, companies may need to reduce shareholdings in conflicting businesses, surrender non-core financial licences, or restructure their holdings.
  • Approval Process: The Bank of Thailand will evaluate the applicants’ explanations on a case-by-case basis and provide recommendations to the Finance Ministry, which holds the final authority for granting licences.
  • Strict Oversight: The BOT has emphasized that there is no policy to replace failed applicants with reserves from the initial round, meaning the final number of virtual banks could be fewer than three.
  • Preparation Phase: Once in-principle approval is granted, successful applicants will be given approximately one year to ensure their systems meet security and financial stability requirements before launching.

The BOT maintains a rigorous stance, indicating that if an applicant fails to meet requirements and cannot provide a valid justification, their license will be at risk. There is no plan to replace disqualified candidates, meaning the market could potentially launch with fewer than three operators.

Advertisement
Continue Reading

Business

Rocket Lab’s Rally Changes Everything For Investors (NASDAQ:RKLB)

Published

on

Rocket Lab's Rally Changes Everything For Investors (NASDAQ:RKLB)

This article was written by

My investing journey began at 15, sparked by a deep curiosity for markets and shaped by my father’s career in finance. What started as a fascination with Warren Buffett’s annual letters quickly evolved into a full-time passion for value investing, mental models, and understanding how great businesses create long-term value. I’ve spent years independently studying financial statements, building DCF models, and analyzing companies through both fundamental and behavioral lenses. While I’m still early in my professional path, I’ve been immersed in the world of investing for nearly a decade. From dissecting shareholder letters to reverse-engineering business strategies, I’ve developed a disciplined, fundamentals-first approach grounded in long-term thinking. I focus on identifying mispriced quality companies and understanding what makes certain business models resilient across cycles. I write on Seeking Alpha to share insights, test ideas in public, and contribute to a community of investors who value clear thinking over hype. My goal is to provide thoughtful, research-backed commentary, whether on under-the-radar compounders, Growth/GARP stocks, or misunderstood tech platforms. Above all, I invest with conviction, patience, and a relentless drive to keep learning.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of RKLB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Madison Diversified Income Fund Q1 2026 Investment Strategy Letter (MBLAX)

Published

on

Invesco SteelPath MLP Alpha Fund Q4 2025 Commentary (MLPAX)

Madison Investments is 100% employee-owned and has been based in Wisconsin’s capital city since its founding in 1974. In that time, Madison has grown from a local firm into a manager entrusted with approximately $22 billion in assets across a suite of mutual funds, active ETFs, managed accounts and customized portfolios. Note: This account is not managed or monitored by Madison Investments, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use Madison Investments’ official channels.

Continue Reading

Business

Hain Celestial remains a work in progress

Published

on

Hain Celestial remains a work in progress

Current innovation is focused on functional attributes and nutrient density. 

Continue Reading

Business

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Q1: 2026-05-05 Earnings Summary

EPS of $0.44 misses by $0.43

 | Revenue of $58.82M (10.28% Y/Y) misses by $3.58M

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call May 12, 2026 8:00 AM EDT

Company Participants

Raymond Furey – Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary
Raul Rodriguez – President, CEO & Director
Lisa Rojkjaer – Executive VP & Chief Medical Officer
Erika Hamilton
David Santos – Executive VP & Chief Commercial Officer

Advertisement

Conference Call Participants

Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Farzin Haque – Jefferies LLC, Research Division
Ashleigh Acker – Piper Sandler & Co., Research Division

Advertisement

Presentation

Operator

Greetings. Welcome to Rigel Pharmaceutical VEPPANU Licensing Agreement Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel’s Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Furey. You may begin.

Advertisement

Raymond Furey
Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary

Welcome to our conference call to discuss Rigel’s in-licensing of VEPPANU or Vepdegestrant. The press release announcing the transaction was issued earlier this morning and can be viewed along with the slides for this presentation in the News and Events section of Investor Relations site on rigel.com.

As a reminder, during today’s call, we may make forward-looking statements regarding our plans and timing for the regulatory review of the transaction and development and commercialization of VEPPANU. In addition, as noted in the press release issued this morning and here in the presentation, this transaction is subject to customary closing conditions, including review under the Hart-Scott-Rodino Antitrust Improvements Act. The statements made today are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks are identified in the slides and in our most recent annual report on Form 10-K for the year ended December

Advertisement
Continue Reading

Business

Monex Group, Inc. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:MNXBF) 2026-05-12

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Tennessee Democrats stripped of House committee seats over redistricting protests

Published

on

Tennessee Democrats stripped of House committee seats over redistricting protests


Tennessee Democrats stripped of House committee seats over redistricting protests

Continue Reading

Business

Cal-Maine acquires frozen food business

Published

on

Cal-Maine acquires frozen food business

Van’s Foods is a manufacturer of frozen breakfast foods. 

Continue Reading

Business

Air India crisis deepens ahead of final Ahmedabad crash report

Published

on

Air India crisis deepens ahead of final Ahmedabad crash report

Air India faces a leadership vacuum and mounting financial losses as it struggles to recover from the crash.

Continue Reading

Business

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Q1: 2026-05-06 Earnings Summary

EPS of -$0.85 misses by $1.33

 | Revenue of -$29.00K (-100.96% Y/Y) misses by $109.31M

Vir Biotechnology, Inc. (VIR) Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDT

Company Participants

Marianne De Backer – President, CEO & Director

Advertisement

Conference Call Participants

Alec Stranahan – BofA Securities, Research Division

Advertisement

Presentation

Alec Stranahan
BofA Securities, Research Division

Thanks for joining the session with Vir Biotechnology. My name is Alec Stranahan. I cover SMID-cap biotech at Bank of America, and I’m the covering analyst for Vir. And it’s my pleasure to introduce Marianne De Backer, Chief Executive Officer of Vir. Marianne, thanks for being here.

Advertisement

Marianne De Backer
President, CEO & Director

Yes, my pleasure. Thank you.

Advertisement

Question-and-Answer Session

Alec Stranahan
BofA Securities, Research Division

Looking forward to the discussion. I guess just jumping right into it, you’ve effectively built a 2-engine value story for Vir. You’ve got the near-term potential from HDV, which we can talk about and the longer-term oncology platform using the PRO-XTEN technology. I guess when you look at how the market is valuing the company today, where do you see the biggest opportunity for re-rating? Is it on HDV approval and launch? Is it on the VIR-5500 progress to registrational studies? Or is it maybe the broader platform as the TCE data matures?

Advertisement

Marianne De Backer
President, CEO & Director

Sure. Yes. Thank you. And thank you, Alec, for hosting us and Bank of America for hosting Vir Biotechnology. So we are very fortunate that at Vir Biotechnology, we have multiple pathways to value creation, as you point out. Obviously, our most advanced program is our delta program, already in registrational trial, initial data are going to read out starting fourth quarter of this year. So obviously, that’s an important route to value creation near term.

And then as you mentioned, we have a portfolio of 3 clinical assets, 3 clinical

Advertisement
Continue Reading

Trending

Copyright © 2025